Circulating tumor cells before and during follow-up after breast cancer surgery.

The presence of circulating tumor cells (CTC) is an independent prognostic factor for progression-free and overall survival for patients with metastatic and newly diagnosed breast cancer. The present study was undertaken to explore whether the presence of CTC before and during follow-up after surgery is associated with recurrence free survival (RFS) and overall survival (OS). In a prospective single center study, CTC were enumerated with the CellSearch system in 30 ml of peripheral blood of 403 stage I-III patients before undergoing surgery for breast cancer (A) and if available 1 week after surgery (B), after adjuvant chemo- and/or radiotherapy or before start of long-term hormonal therapy (C), one (D), two (E) and three (F) years after surgery. Patients were stratified into unfavorable (CTC≥1) and favorable (CTC=0) prognostic groups. >1 CTC in 30 ml blood was detected in 75/403 (19%) at A, 66/367 (18%) at B, 40/263 (15%) at C, 30/235 (12%) at D, 18/144 (11%) at E and 11/83 (13%) at F. RFS and OS was significantly lower for unfavorable CTC as compared to favorable CTC before surgery (p=0.022 and p=0.006), after adjuvant therapy (p<0.001 and p=0.018) and one (p=0.006 and p=0.013) and two (p<0.001 and p=0.045) years after surgery, but not 1 week post-surgery. The presence of CTC in blood drawn pre and one and two years after surgery, but not post-surgery is associated with shorter RFS and OS for stage I-III breast cancer.

[1]  Sanjay Shete,et al.  uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues , 2006, Proceedings of the National Academy of Sciences.

[2]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[3]  A. Vincent-Salomon,et al.  Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  M. Rezai,et al.  Prognostic relevance of circulating tumor cells (CTC) before adjuvant chemotherapy in patients with breast cancer: Results of the German SUCCESS trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Stoecklein,et al.  Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer , 2002, The Lancet.

[6]  K. Schütze,et al.  Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. , 2000, The American journal of pathology.

[7]  M. Campone,et al.  High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Istvan Vermes,et al.  Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer , 2012, Breast Cancer Research.

[9]  T. Fehm,et al.  Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. , 2014, The Lancet. Oncology.

[10]  Debjani Dutta,et al.  Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. , 2004, The American journal of pathology.

[11]  H. Kuerer,et al.  Circulating tumour cells in non-metastatic breast cancer: a prospective study. , 2012, The Lancet. Oncology.

[12]  Anne Vincent-Salomon,et al.  Circulating Tumor Cell Detection Predicts Early Metastatic Relapse After Neoadjuvant Chemotherapy in Large Operable and Locally Advanced Breast Cancer in a Phase II Randomized Trial , 2008, Clinical Cancer Research.

[13]  Jonathan W. Uhr,et al.  Controversies in clinical cancer dormancy , 2011, Proceedings of the National Academy of Sciences.

[14]  Tanja Fehm,et al.  HER-2 gene amplification can be acquired as breast cancer progresses. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[16]  Tanja Fehm,et al.  Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  T. Schrijver,et al.  Detection of cancer before distant metastasis , 2013 .

[18]  Karen A Gelmon,et al.  Population-based validation of the prognostic model ADJUVANT! for early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[20]  Mieke Schutte,et al.  Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells , 2009, Journal of the National Cancer Institute.

[21]  L. Terstappen,et al.  Towards the Biological Understanding of CTC: Capture Technologies, Definitions and Potential to Create Metastasis , 2013, Cancers.

[22]  C. Lim,et al.  Isolation and retrieval of circulating tumor cells using centrifugal forces , 2013, Scientific Reports.

[23]  R. Spang,et al.  Predicting the clinical status of human breast cancer by using gene expression profiles , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Bilous,et al.  Use of the St Gallen classification for patients with node‐negative breast cancer may lead to overuse of adjuvant chemotherapy , 2002, The British journal of surgery.

[25]  J. Aerssens,et al.  Efficiency of whole genome amplification of single circulating tumor cells enriched by CellSearch and sorted by FACS , 2013, Genome Medicine.

[26]  Anne-Michelle Noone,et al.  Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Lluch,et al.  Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  I. Vermes,et al.  Importance of circulating tumor cells in newly diagnosed colorectal cancer. , 2015, International journal of oncology.

[29]  Mikael Lundin,et al.  Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series. , 2006, European journal of cancer.

[30]  Markus Beck,et al.  Filter Characteristics Influencing Circulating Tumor Cell Enrichment from Whole Blood , 2013, PloS one.

[31]  S. Braun,et al.  Circulating tumor cells in metastatic breast cancer--toward individualized treatment? , 2004, The New England journal of medicine.

[32]  R. Vessella,et al.  Tumor cell dormancy: An NCI workshop report , 2007, Cancer biology & therapy.

[33]  Peter Dalgaard,et al.  R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .

[34]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[35]  Jonathan W. Uhr,et al.  Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.

[36]  L. Terstappen,et al.  Characterization of circulating tumor cells by fluorescence in situ hybridization , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[37]  T. Fehm,et al.  Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients , 2013, Proceedings of the National Academy of Sciences.

[38]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[39]  T. Fehm,et al.  A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation , 2006, Cancer.

[40]  S. Sleijfer,et al.  CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. , 2012, Cancer letters.

[41]  T. Fehm,et al.  A pooled analysis of bone marrow micrometastasis in breast cancer. , 2005, The New England journal of medicine.

[42]  Tanja Fehm,et al.  Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer , 2016, Clinical Cancer Research.

[43]  J. Uhr,et al.  Challenges in the Enumeration and Phenotyping of CTC , 2012, Clinical Cancer Research.

[44]  Tanja Fehm,et al.  Circulating Tumor Cells in Patients with Breast Cancer Dormancy , 2004, Clinical Cancer Research.

[45]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[46]  L. Terstappen,et al.  Interpretation of changes in circulating tumor cell counts. , 2012, Translational oncology.

[47]  Leon W. M. M. Terstappen,et al.  Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival , 2011, PloS one.